1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > The World Market for Cancer Therapeutics by Product

The World Market for Cancer Therapeutics by Product

  • November 2015
  • -
  • Kalorama Information
  • -
  • 320 pages

This report, the World Market for Cancer Therapeutics presents a detailed picture of the market for cancer drugs, with a focus on novel therapies. The market analysis in this report includes analysis of products avaiable for each cancer type (Breast Cancer, Lung Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Colon Cancer and Other types) including Monoclonal Antibodies, Tyrosine Kinase, Inhibitors, Cancer Vaccines, Cytokines, Gene Therapy, Traditional Chemotherapy.

The report has a special emphasis on novel treatments and provides an overview of treatments on the market and in development for each cancer type. Trend analysis, market share and company profiles of over 50 major players, smaller participants and new entrants is a part of the market analysis in this report.

Secondary and primary research was used to determine market size for cancer types by product sales in this report. Methodology included telephone interviews and email correspondence with company representatives, researchers, government representatives, and physicians. These interviews were conducted with the purpose of capturing the perspectives from industry participants on the market opportunity and current trends.

All market data pertains to the world market at the manufacturers’ level. The base year for data was 20 5. Historical data was provided for the years 20 0 through 20 4, with forecast data provided for 20 6 through 2020. Compound annual growth rates (CAGRs) are provided for the 20 0-20 5, 20 5-2020 and 20 0-2020 periods for each segment covered. Competitive analysis is provided for the year 20 5. The forecasted market analysis for 20 5-2020 was based on probability of approval and sales of products in late stage development, competitive trends, product marketing, cancer epidemiology, and demographic trends.

Companies covered include Novartis, Pfizer, Abbvie, Bayer, Merck and many other companies.

Table Of Contents

The World Market for Cancer Therapeutics by Product
ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Size and Growth of the Market
TWO: INTRODUCTION, NOVEL AND TRADITIONAL APPROACHES
What is Cancer
Biochemistry of Cancer Cells
Carcinogen Metabolism
Causes of Cancer Growth
History and Growth of the Cancer Treatment Market
How Personalized Medicine is Changing the Cancer Market
Targeted Cancer Therapy
Genetic Testing in Cancer
Industry Structure
Cancer Treatment Approaches: Traditional vs. Novel
Product Examples
Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Cancer Vaccines
Cytokines
Gene Therapy
Other Novel Classifications
THREE: MARKET DRIVERS / BARRIERS
Global Cancer Impact
Life Expectancy and Cancer
The United States - The Real Cost of Cancer
Curing Cancer⎯The Ultimate Goal
The Cost of Cancer Therapies
Healthy People 2020
Marketing and Distribution Trends
Elderly Clinical Trial Involvement
Development Risk
Development Risk in Novel Cancer Therapy Research⎯Allovectin-7
Development Programs
What Does the Novel Therapy Development Pipeline Look Like?
Recent NDA Activity
New Indications
Reaching the Market: Regulatory Accelerated Approvals and Priority Reviews
Development and Marketing Agreements
Insurance and Reimbursement Issues
FOUR: NOVEL THERAPIES IN BLADDER CANCER TREATMENT
Bladder Cancer Overview
Trends in Incidence and Mortality
Treating Bladder Cancer
Novel Treatment Research Activities
Developer Participation
Bladder Cancer Treatment Market and Opportunity
Novel Treatment Outlook
FIVE: NOVEL THERAPIES IN BRAIN CANCER TREATMENT
Brain Cancer Overview
Trends in Incidence and Mortality
Treating Brain Cancer
Novel Treatment Research Activities
Developer Participation
Brain Cancer Treatment Market and Opportunity
Novel Treatment Outlook
SIX: NOVEL THERAPIES IN BREAST CANCER TREATMENT
Breast Cancer Overview
Trends in Incidence and Mortality
Treating Breast Cancer
Novel Treatment Research Activities
Developer Participation
Breast Cancer Treatment Market and Opportunity
Novel Treatment Outlook
Leading Products and Suppliers
SEVEN: NOVEL THERAPIES IN COLORECTAL CANCER TREATMENT115
Colorectal Cancer Overview
Trends in Incidence and Mortality
Treating Colorectal Cancer
Novel Treatment Research Activities
Developer Participation
Colorectal Cancer Treatment Market and Opportunity
Novel Treatment Outlook
Leading Products and Suppliers
EIGHT: NOVEL THERAPIES IN KIDNEY CANCER TREATMENT
Kidney Cancer Overview
Trends in Incidence and Mortality
Treating Kidney Cancer
Novel Treatment Research Activities
Developer Participation
Kidney Cancer Treatment Market and Opportunity
Novel Treatment Outlook
Leading Products and Suppliers
NINE: NOVEL THERAPIES IN LEUKEMIA TREATMENT
Leukemia Cancer Overview
Trends in Incidence and Mortality
Treating Leukemia
Novel Treatment Research Activities
Developer Participation
Leukemia Treatment Market and Opportunity
Novel Treatment Outlook
Leading Products and Suppliers
TEN: NOVEL THERAPIES IN LIVER CANCER TREATMENT
Liver Cancer Overview
Trends in Incidence and Mortality
Treating Liver Cancer
Novel Treatment Research Activities
Developer Participation
Liver Cancer Treatment Market and Opportunity
Novel Treatment Outlook
ELEVEN: NOVEL THERAPIES IN LUNG CANCER TREATMENT
Lung Cancer Overview
Trends in Incidence and Mortality
Treating Lung Cancer
Novel Treatment Research Activities
Developer Participation
Lung Cancer Treatment Market and Opportunity
Novel Treatment Outlook
Leading Products and Suppliers
TWELVE: NOVEL THERAPIES IN LYMPHOMA TREATMENT
Lymphoma Overview
Trends in Incidence and Mortality
Treating Lymphoma
Novel Treatment Research Activities
Developer Participation
Lymphoma Treatment Market and Opportunity
Novel Treatment Outlook
Leading Products and Suppliers
Figure 12-8
THIRTEEN: NOVEL THERAPIES IN MELANOMA TREATMENT
Melanoma Overview
Trends in Incidence and Mortality
Treating Melanoma
Novel Treatment Research Activities
Developer Participation
Melanoma Treatment Market and Opportunity
Novel Treatment Outlook
Leading Products and Suppliers
FOURTEEN: NOVEL THERAPIES IN MULTIPLE MYELOMA TREATMENT
Myeloma Overview
Trends in Incidence and Mortality
Treating Multiple Myeloma
Novel Treatment Research Activities
Developer Participation
Multiple Myeloma Treatment Market and Opportunity
Novel Treatment Outlook
Leading Products and Suppliers
FIFTEEN: NOVEL THERAPIES IN PANCREATIC CANCER TREATMENT229
Pancreatic Cancer Overview
Trends in Incidence and Mortality
Treating Pancreatic Cancer
Novel Treatment Research Activities
Developer Participation
Pancreatic Cancer Treatment Market and Opportunity
Novel Treatment Outlook and Suppliers' Market Impact
SIXTEEN: NOVEL THERAPIES IN PROSTATE CANCER TREATMENT 239
Prostate Cancer Overview
Trends in Incidence and Mortality
Treating Prostate Cancer
Novel Treatment Research Activities
Developer Participation
Prostate Cancer Treatment Market and Opportunity
Novel Treatment Outlook and Suppliers' Market Impact
SEVENTEEN: NOVEL CANCER THERAPIES: MARKET SUMMARY
Overview
How Have Novel Therapies Shaped the Market and What's In store for the Future?252
Novel Therapies and its Impact on Individual Cancer Markets
Geographical Market and Trends
Competitive Landscape
EIGHTEEN: MARKET PARTICIPANTS AND KEY DEVELOPERS
Introduction
AbbVie
Acerta Pharma
Adaptimmune
Advantagene
Altor BioScience
Amgen
Apceth GmbH and Co. KG
Array BioPharma
Astex Pharmaceuticals
AstraZeneca plc
Bayer
Bellicum Pharmaceuticals, Inc.
BioCancell Ltd.
Bluebird Bio
Boehringer Ingelheim
Boston Biomedical
Bristol-Myers Squibb Company
Caladrius (NeoStem)
Celgene
Celldex Therapeutics
Celsion Corporation
Clovis Oncology
Cold Genesys, Inc.
Daiichi Sankyo
Eisai
Eli Lilly and Company
EMD Serono
Galena Biopharma
Gamida Cell
Genprex, Inc.
Gilead Sciences
Immunomedics
Incyte
Inovio
Johnson and Johnson
Juno Therapeutics
Karyopharm Therapeutics
MaxiVAX
MedImmune
Merck and Company
Millennium (Takeda Oncology)
Momotaro-Gene, Inc.
MultiVir, Inc.
Northwest Biotherapeutics
Novartis
Oncolytics Biotech
OncoMed
OncoSec Medical, Inc.
Pfizer, Inc.
Roche
Sanofi
Seattle Genetics
Sevion Therapeutics
Takara Bio
Tocagen
VBL Therapeutics
ZIOPHARM Oncology, Inc.
INFORMATION SOURCES


LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY
Figure 1-1
Cancer Therapeutics Market, 2010-2020
Table 1-1
Novel Cancer Therapies Market, 2010-2020
Figure 1-2
Novel Cancer Therapies Market, 2010-2020
TWO: CANCER INDUSTRY DEVELOPMENT
Table 2-1
Viruses Associated with Cancer in Humans
Figure 2-1
Approved Cancer Therapies in the United States by Primary Indication
Figure 2-2
Market Value for Traditional vs. Novel Cancer Therapies
Figure 2-3
Market Distribution: Traditional vs. Novel Cancer
Figure 2-4
Leading Chemotherapy Treatments by 2015 Estimated Sales
Figure 2-5
Leading Hormone Cancer Treatments by 2015 Estimated Sales
Figure 2-6
Antibody Conjugates in Development by Phase
Figure 2-7
Antibody Conjugates in Development by Cancer Type
THREE: MARKET DRIVERS / BARRIERS
Table 3-1
Global Cancer Incidence by Selected Types of Cancer, 2012 and 2025, all races, all
ages, both genders
Figure 3-1
Estimated and Projected Global Cancer Incidence by Selected Types of Cancer, 2012
and 2025
Table 3-2
Most Common Cancer by Region and Gender
Table 3-3
Five-year Net Survival Rates* (%) for Selected Cancers among Adults 15 Years of Age
and Older in Select Countries, Average 2005-2009
Figure 3-2
United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both
Sexes, 2009
Figure 3-3
United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both
Sexes, 2009
Figure 3-4
Novel Cancer Compounds in Development by Phase of Development
Figure 3-5
Novel Therapy Developments by Cancer Type
Figure 3-6
Phase III: Novel Cancer Compounds in Development for Major Indications,
Distribution Estimates
Figure 3-7
Phase II: Novel Cancer Compounds in Development for Major Indications, Distribution
Estimates
Figure 3-8
Phase I: Novel Cancer Compounds in Development for Major Indications, Distribution
Estimates
Table 3-4
Select NDA Activity: 2015
Table 3-5
Select New Indications, 2015
FOUR: NOVEL THERAPIES IN BLADDER CANCER TREATMENT
Figure 4-1
Global Incidence and Mortality of Bladder Cancer by Country, 2012
Figure 4-2
Research Activities in Novel Bladder Cancer Treatment by Classification
Figure 4-3
Bladder Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of
Development
Figure 4-4
Global Bladder Cancer Treatment Market, 2010-2020
Figure 4-5
Distribution of Sales by Broad Classification: Bladder Cancer Treatments, 2015
Figure 4-6
Novel Treatments for Bladder Cancer by Drug Classification, 2010-2020
FIVE: NOVEL THERAPIES IN BRAIN CANCER TREATMENT
Figure 5-1
Global Incidence and Mortality of Brain Cancer by Country, 2012
Figure 5-2
Research Activities in Novel Brain Cancer Treatment by Classification
Figure 5-3
Brain Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of
Development
Figure 5-4
Global Brain Cancer Treatment Market, 2010-2020
Figure 5-5
Distribution of Sales by Broad Classification: Brain Cancer Treatments, 2015
Figure 5-6
Novel Treatments for Brain Cancer by Drug Classification, 2010-2020
SIX: NOVEL THERAPIES IN BREAST CANCER TREATMENT
Figure 6-1
Global Incidence and Mortality of Breast Cancer by Country, 2012
Figure 6-2
Research Activities in Novel Breast Cancer Treatment by Classification
Figure 6-3
Breast Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of
Development
Figure 6-4
Global Breast Cancer Treatment Market, 2010-2020
Figure 6-5
Distribution of Sales by Broad Classification: Breast Cancer Treatments, 2015
Figure 6-6
Novel Treatments for Breast Cancer by Drug Classification, 2010-2020
Figure 6-7
Leading Novel Products in Breast Cancer Treatment based on Revenues, 2010-2015 111
Figure 6-8
Leading Novel Products in Breast Cancer Treatment based on Revenues, Market Share,
Estimated 2015
Figure 6-9
Breast Cancer Novel Therapies: Leading Suppliers Shares by Market Revenues,
Estimated 2015
SEVEN: NOVEL THERAPIES IN COLORECTAL CANCER TREATMENT
Figure 7-1
Global Incidence and Mortality of Colorectal Cancer by Country, 2012
Figure 7-2
Research Activities in Novel Colorectal Cancer Treatment by Classification
Figure 7-3
Colorectal Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase
of Development
Figure 7-4
Global Colorectal Cancer Treatment Market, 2010-2020
Figure 7-5
Distribution of Sales by Broad Classification: Colorectal Cancer Treatments, 2015
Figure 7-6
Novel Treatments for Colorectal Cancer by Drug Classification, 2010-2020
Table 7-7
Leading Novel Products in Colorectal Cancer Treatment based on Revenues, 2010-2015126
Figure 7-8
Leading Novel Products in Colorectal Cancer Treatment based on Revenues, Market
Share, Estimated 2015
Figure 7-9
Colorectal Cancer Novel Therapies: Leading Suppliers Shares by Market Revenues,
Estimated 2015
EIGHT: NOVEL THERAPIES IN KIDNEY CANCER TREATMENT
Figure 8-1
Global Incidence and Mortality of Kidney Cancer by Country, 2012
Figure 8-2
Research Activities in Novel Kidney Cancer Treatment by Classification
Figure 8-3
Kidney Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of
Development
Figure 8-4
Global Kidney Cancer Treatment Market, 2010-2020
Figure 8-5
Distribution of Sales by Broad Classification: Kidney Cancer Treatments, 2015
Figure 8-6
Novel Treatments for Kidney Cancer by Drug Classification, 2010-2020
Table 8-7
Leading Novel Products in Kidney Cancer Treatment based on Revenues, 2010-2015138
Figure 8-8
Leading Novel Products in Kidney Cancer Treatment based on Revenues, Market
Share, Estimated 2015
Figure 8-9
Kidney Cancer Novel Therapies: Leading Suppliers Shares by Market Revenues,
Estimated 2015
NINE: NOVEL THERAPIES IN LEUKEMIA TREATMENT
Table 9-1
Leukemia Overview by Type
Figure 9-1
Distribution of Leukemia Cases by Type
Figure 9-2
Global Incidence and Mortality of Leukemia by Country, 2012
Figure 9-3
Research Activities in Novel Leukemia Treatment by Classification
Figure 9-4
Leukemia Potential Targeted/Novel Therapies Development Pipeline by Phase of
Development
Figure 9-5
Global Leukemia Treatment Market, 2010-2020
Figure 9-6
Distribution of Sales by Broad Classification: Leukemia Treatments, 2015
Figure 9-7
Novel Treatments for Leukemia by Drug Classification, 2010-2020
Figure 9-8
Leading Novel Products in Leukemia Treatment based on Revenues, 2010-2015
Figure 9-9
Leading Novel Products in Leukemia Treatment based on Revenues, Market Share,
Estimated 2015
Figure 9-10
Leukemia Novel Therapies: Leading Suppliers Shares by Market Revenues, Estimated
2015
TEN: NOVEL THERAPIES IN LIVER CANCER TREATMENT
Figure 10-1
Global Incidence and Mortality of Liver Cancer by Country, 2012
Figure 10-2
Research Activities in Novel Liver Cancer Treatment by Classification
Figure 10-3
Liver Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of
Development
Figure 10-4
Global Liver Cancer Treatment Market, 2010-2020
Figure 10-5
Distribution of Sales by Broad Classification: Liver Cancer Treatments, 2015
ELEVEN: NOVEL THERAPIES IN LUNG CANCER TREATMENT
Table 11-1
Types of Primary Lung Cancer
Figure 11-1
Global Incidence and Mortality of Lung Cancer by Country, 2012
Figure 11-2
Research Activities in Novel Lung Cancer Treatment by Classification
Figure 11-3
Lung Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of
Development
Figure 11-4
Global Lung Cancer Treatment Market, 2010-2020
Figure 11-5
Distribution of Sales by Broad Classification: Lung Cancer Treatments, 2015
Figure 11-6
Novel Treatments for Lung Cancer by Drug Classification, 2010-2020
Figure 11-7
Leading Novel Products in Lung Cancer Treatment based on Revenues, 2010-2015.. 181
Figure 11-8
Leading Novel Products in Lung Cancer Treatment based on Revenues, Market Share,
Estimated 2015
Figure 11-9
Lung Cancer Novel Therapies: Leading Suppliers Shares by Market Revenues,
Estimated 2015
TWELVE: NOVEL THERAPIES IN LYMPHOMA TREATMENT
Table 12-1
Classification of Non-Hodgkin’s Lymphomas
Figure 12-1
Global Incidence and Mortality of Lymphoma by Country, 2012
Figure 12-2
Research Activities in Novel Lymphoma Treatment by Classification
Figure 12-3
Lymphoma Potential Targeted/Novel Therapies Development Pipeline by Phase of
Development
Figure 12-4
Global Lymphoma Treatment Market, 2010-2020
Figure 12-5
Distribution of Sales by Broad Classification: Lymphoma Treatments, 2015
Figure 12-6
Novel Treatments for Lymphoma by Drug Classification, 2010-2020
Figure 12-7
Leading Novel Products in Lymphoma Treatment based on Revenues, 2010-2015
Lymphoma Novel Therapies: Leading Suppliers Shares by Market Revenues, Estimated
2015
THIRTEEN: NOVEL THERAPIES IN MELANOMA TREATMENT
Table 13-1
Malignant Conditions of the Skin
Figure 13-1
Global Incidence and Mortality of Melanoma by Country, 2012
Figure 13-2
Research Activities in Novel Melanoma Treatment by Classification
Figure 13-3
Melanoma Potential Targeted/Novel Therapies Development Pipeline by Phase of
Development
Figure 13-4
Global Melanoma Treatment Market, 2010-2020
Figure 13-5
Distribution of Sales by Broad Classification: Melanoma Treatments, 2015
Figure 13-6
Novel Treatments for Melanoma by Drug Classification, 2010-2020
Figure 13-7
Leading Novel Products in Melanoma Treatment based on Revenues, 2010-2015
Figure 13-8
Leading Novel Products in Melanoma Treatment based on Revenues, Market Share,
Estimated 2015
Figure 13-9
Melanoma Novel Therapies: Leading Suppliers Shares by Market Revenues, Estimated
2015
FOURTEEN: NOVEL THERAPIES IN MULTIPLE MYELOMA
TREATMENT
Figure 14-1
Global Incidence and Mortality of Multiple Myeloma by Country, 2012
Figure 14-2
Research Activities in Novel Multiple Myeloma Treatment by Classification
Figure 14-3
Multiple Myeloma Potential Targeted/Novel Therapies Development Pipeline by Phase
of Development
Figure 14-4
Global Multiple Myeloma Treatment Market, 2010-2020
Figure 14-5
Distribution of Sales by Broad Classification: Multiple Myeloma Treatments, 2015 .. 223
Figure 14-6
Novel Treatments for Multiple Myeloma by Drug Classification, 2010-2020
Table 14-7
Leading Novel Products in Multiple Myeloma Treatment based on Revenues, 2010-
2015
Figure 14-8
Multiple Myeloma Novel Therapies: Leading Suppliers Shares by Market Revenues,
Estimated 2015
FIFTEEN; NOVEL THERAPIES IN PANCREATIC CANCER TREATMENT229
Figure 15-1
Global Incidence and Mortality of Pancreatic Cancer by Country, 2012
Figure 15-2
Research Activities in Novel Pancreatic Cancer Treatment by Classification
Figure 15-3
Pancreatic Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase
of Development
Figure 15-4
Global Pancreatic Cancer Treatment Market, 2010-2020
Figure 15-5
Distribution of Sales by Broad Classification: Pancreatic Cancer Treatments, 2015
Figure 15-6
Novel Treatments for Pancreatic Cancer by Drug Classification, 2010-2020
SIXTEEN: NOVEL THERAPIES IN PROSTATE CANCER TREATMENT 239
Figure 16-1
Global Incidence and Mortality of Prostate Cancer by Country, 2012
Figure 16-2
Research Activities in Novel Prostate Cancer Treatment by Classification
Figure 16-3
Prostate Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of
Development
Figure 16-4
Global Prostate Cancer Treatment Market, 2010-2020
Figure 16-5
Distribution of Sales by Broad Classification: Prostate Cancer Treatments, 2015
Figure 16-6
Novel Treatments for Prostate Cancer by Drug Classification, 2010-2020
SEVENTEEN: NOVEL CANCER THERAPIES: MARKET SUMMARY
Table 17-1
Novel Cancer Therapies, Global Market Value by Classification, 2010-2020
Figure 17-1
Novel Cancer Therapies, Global Market Value by Classification, 2010-2020
Figure 17-2
Novel Cancer Therapies, Market Share by Classification of Treatment, 2015
Figure 17-3
Novel Therapy Potential by Cancer Type, 2015 and 2020 Estimates
Figure 17-4
Distribution of Novel Cancer Therapy Potential in Cancer, by Type, 2020
Figure 17-4
Novel Cancer Therapy Market by Broad Region, 2015 Estimated Distribution
Table 17-2
Novel Cancer Therapy Market, Leading Suppliers’ Shares by Market Revenues, 2015263
Figure 17-5
Novel Cancer Therapy Market, Leading Suppliers’ Market Share, 2015
EIGHTEEN: MARKET PARTICIPANTS AND KEY DEVELOPERS
Figure 18-1
Novel Cancer Therapies in Development for Leading Companies
INFORMATION SOURCES

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.